title: Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis.
abstract: The apolipoprotein (apo)A-I/C-III/A-IV gene cluster is involved in lipid metabolism and atherosclerosis. Overexpression of apoC-III in mice causes hypertriglyceridemia and induces atherogenesis, whereas overexpression of apoA-I or apoA-IV increases cholesterol in plasma high density lipoprotein (HDL) and protects against atherosclerosis. Each gene has been studied alone in transgenic mice but not in combination as the entire cluster. To determine which phenotype is produced by the expression of the entire gene cluster, transgenic mice were generated with a 33-kb human DNA fragment. The results showed that the transgene contained the necessary elements to direct hepatic and intestinal expression of the 3 genes. In the pooled data, plasma concentrations were 257+/-9, 7.1+/-0.5, and 1.0+/-0.2 mg/dL for human apoA-I, apoC-III, and apoA-IV, respectively (mean+/-SEM). Concentrations of these apolipoproteins were higher in males than in females. Human apoA-I and apoC-III concentrations were positively correlated, suggesting that they are coregulated. Transgenic mice exhibited gross hypertriglyceridemia and accumulation of apoB(48)-containing triglyceride-rich lipoproteins. Plasma triglyceride and cholesterol concentrations were correlated positively with human apoC-III concentration, and HDL cholesterol was correlated with apoA-I concentration. In an apoE-deficient background, despite being markedly hypertriglyceridemic, cluster transgenic animals compared with nontransgenic animals showed a 61% reduction in atherosclerosis. This suggests that apoA-I and/or apoA-IV can protect against atherosclerosis even in the presence of severe hyperlipidemia. These mice provide a new model for studies of the regulation of the 3 human genes in combination.
authors.affiliation: Unité d'Expression des Gènes Eucaryotes, Institut Pasteur, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Vergnes
authors.forename: N
authors.initials: N
authors.lastname: Baroukh
authors.forename: M A
authors.initials: MA
authors.lastname: Ostos
authors.forename: G
authors.initials: G
authors.lastname: Castro
authors.forename: N
authors.initials: N
authors.lastname: Duverger
authors.forename: M N
authors.initials: MN
authors.lastname: Nanjee
authors.forename: J
authors.initials: J
authors.lastname: Najib
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: N E
authors.initials: NE
authors.lastname: Miller
authors.forename: M M
authors.initials: MM
authors.lastname: Zakin
authors.forename: A
authors.initials: A
authors.lastname: Ochoa
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000032:analysis / Q000235:genetics*; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A / Q000235:genetics*; D001055:Apolipoproteins B / Q000097:blood / Q000737:chemistry; D001056:Apolipoproteins C / Q000032:analysis / Q000235:genetics*; D001161:Arteriosclerosis / Q000235:genetics / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D005786:Gene Expression Regulation; D006949:Hyperlipidemias / Q000097:blood / Q000235:genetics*; D008074:Lipoproteins / Q000097:blood / Q000737:chemistry; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D005810:Multigene Family; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D008074:Lipoproteins; D014280:Triglycerides; C022205:apolipoprotein A-IV